Chief Pharmaceutical Inspector

IWSC.405.23.2019. ES.1-1
WTC/0079_01_02/133

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC and Art. 80(5) of Directive 2001/82/EC as amended

Chief Pharmaceutical Inspector
/the Competent Authority of Poland/

confirms the following:

the manufacturer

Sieć Badawcza Łukasiewicz – Instytut Chemii Przemysłowej im. Prof. Ignacego Mościckiego ul. Rydygiera 8, 01-793 Warszawa, POLAND

site address

Sieć Badawcza Łukasiewicz – Instytut Chemii Przemysłowej im. Prof. Ignacego Mościckiego ul. Rydygiera 8, 01-793 Warszawa, POLAND

is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC and Art. 80(1) of Directive 2001/82/EC transposed in Pharmaceutical Law of 6th of September 2001 (Journal of Laws from 2019, item 499) in connection with registration no **1/WTC0079/API/15**.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **05-08/03/2019,** it is considered that it complies with the Good Manufacturing Practice requirements laid down in Directive 2003/94/EC, Directive 91/412/EEC and the principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMP. If it does not appear, please contact the issuing authority.

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

GŁÓWNY INSPEKTOR FARMACEUTYCZNY

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Alfacalcidol - Calcifediol monohydrate - Calcipotriol anhydrous - Paricalcitol - Brynzolamide

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.2 Manufacture of crude active substance** **3.1.3 Purification steps** (crystallisation)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

GŁÓWNY INSPEKTOR FARMACEUTYCZNY

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Tacalcitol monohydrate

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.2 Manufacture of crude active substance** **3.1.3 Purification steps** (preparative HPLC, crystallisation)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

GŁÓWNY INSPEKTOR FARMACEUTYCZNY

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Anastrozole

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.2 Manufacture of crude active substance** **3.1.3 Purification steps** (chromatographic column, crystallisation)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying, milling) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

GŁÓWNY INSPEKTOR FARMACEUTYCZNY

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Olmesartan medoxomil

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.3 Purification steps** (crystallisation)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying, milling) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

INSPEKTOR FARMACEUTYCZNY WMO79

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Latanoprost

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.2 Manufacture of crude active substance** **3.1.3 Purification steps** (preparative HPLC)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

INSPEKTOR FARMACEUTYCZNY WMO79

Paweł Piotrowski
Chief Pharmaceutical Inspector

Part 2

3 MANUFACTURING OPERATIONS – ACTIVE SUBSTANCES **Active Substance(s):** - Imatinib Mesylate - Imatinib Mesylate G

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates **3.1.2 Manufacture of crude active substance** **3.1.3 Purification steps** (crystallisation)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps (drying, milling, mixing or drying, milling, mixing, granulation, drying, mixing) **3.5.2 Primary Packaging** (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) **3.5.3 Secondary Packaging** (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance) **3.5.4 Other** (storage, distribution)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

date: 2020 -12- 23

Chief Pharmaceutical Inspectorate
ul. Senatorska 12, 00-082 Warszawa, Poland
Tel. +48 22 635 99 51, fax. +48 22 635 99 57

INSPEKTOR FARMACEUTYCZNY WARSZAWA

Paweł Piotrowski
Chief Pharmaceutical Inspector